SCHEMBL1177704

SCHEMBL1177704

Nc1ccc(Oc2ccc3ccccc3c2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.65
MAPT P10636 4/20 0.65
MEN1 O00255 3/20 0.65
KMT2A Q03164 3/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
GAA P10253 2/20 0.65
MITF O75030 1/20 0.65
GFER P55789 1/20 0.65
NLRP1 Q9C000 1/20 0.65
NOD2 Q9HC29 1/20 0.65
MAOA P21397 3/20 0.64
CYP3A4 P08684 3/20 0.61
TDP1 Q9NUW8 2/20 0.61
TSHR P16473 1/20 0.61
HSD17B10 Q99714 2/20 0.60
RCE1 Q9Y256 1/20 0.60
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
NLRP3 Q96P20 1/20 0.57
LMNA P02545 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31536331 1.00 ALDH1A1 (0.65) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL30209491 0.91 ALDH1A1 (0.67) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL1368972 0.91 ALDH1A1 (0.67) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL7907957 0.91 ALDH1A1 (0.74) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL554296 0.90 GAA (0.70) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL29467789 0.90 GAA (0.70) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL395026 0.86 CYP1A2 (0.64) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL29366638 0.86 CYP1A2 (0.64) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL4402154 0.84 LTA4H (0.60) MAPTMEN1KMT2AGAAMAOA
SCHEMBL29860094 0.84 LTA4H (0.60) MAPTMEN1KMT2AGAAMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12161648-B2 Covalent targeting of E3 ligases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-10 US disclosed
US-20230142839-A1 N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases ARRAY BIOPHARMA INC. (US) 2023-05-11 US disclosed
CN-109651208-B N-aryl sulfonamide compound, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2022-01-04 CN disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
EP-3863642-A1 COVALENT TARGETING OF E3 LIGASES The Regents of the University of California (US) 2021-08-18 EP disclosed
CN-113164495-A Covalent targeting of E3 ligase 加利福尼亚大学董事会 2021-07-23 CN disclosed
US-20170252317-A1 N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES ARRAY BIOPHARMA, INC. 2017-09-07 US disclosed
US-9693989-B2 N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases ARRAY BIOPHARMA, INC. (US) 2017-07-04 US disclosed
US-8648087-B2 N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases ARRAY BIOPHARMA, INC. (US) 2014-02-11 US disclosed
US-20140023643-A1 N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES ARRAY BIOPHARMA, INC. (US) 2014-01-23 US disclosed
EP-1482931-A2 MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE Transtech Pharma, Inc. (US) 2004-12-08 EP disclosed
US-20040082542-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-04-29 US disclosed
WO-2003075921-A2 MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE TRANSTECH PHARMA, INC. (US) 2003-09-18 WO disclosed
US-5886131-A Method for preparing 1,4-Bis(4-aminophenoxy)naphthalene and its polymers CHINA TEXTILE INSTITUTE (TW) 1999-03-23 US disclosed
EP-0050321-B1 NOVEL BICYCLOOXYPHENYL UREAS, PROCESS FOR THEIR PREPARATION AND PESTICIDES CONTAINING THEM UNION CARBIDE CORPORATION (US) 1985-08-21 EP disclosed
US-4399072-A HERBICIDE, FUNGICIDE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1983-08-16 US disclosed
US-4280835-A Herbicidal N-phenyl-N-methylurea derivatives SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1981-07-28 US disclosed
US-4275077-A Insecticidal acyl urea derivatives CELAMERCK GMBH & CO. KG (DE) 1981-06-23 US disclosed
EP-0013414-A2 Urea derivatives, process for their preparation and their use as insecticides CELAMERCK GmbH & Co. KG (DE) 1980-07-23 EP disclosed
US-3956264-A Basic azo dyestuffs having indolyl-methyleneamino substituent in the diazo component BAYER AKTIENGESELLSCHAFT (DT) 1976-05-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140023643-A1 N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES ERBB4, ERBB2, ERBB3 ALDH1A1 2816/4885MAPT 4303/4885MEN1 886/4885
US-20040082542-A1 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents AGER, S100A4, S100B ALDH1A1 3202/4885MAPT 406/4885MEN1 1605/4885
US-12161648-B2 Covalent targeting of E3 ligases RNF114, RNF4, RNF168 ALDH1A1 2969/4885MAPT 961/4885MEN1 2638/4885
US-20230142839-A1 N4-phenyl-quinazoline-4 -amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases ERBB4, ERBB2, ERBB3 ALDH1A1 2816/4885MAPT 4303/4885MEN1 886/4885
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES RNF114, RNF4, RNF168 ALDH1A1 2969/4885MAPT 961/4885MEN1 2638/4885
US-20170252317-A1 N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES ERBB4, ERBB2, ERBB3 ALDH1A1 2816/4885MAPT 4303/4885MEN1 886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.